Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2025/07/21 07:00 EDT
Pre Market
Last
 44.6
+0.13 (+0.29%)
Bid
44.5
Ask
44.8
High 45 
Low 44.6 
Volume 21 
Regular Hours
Last
 44.47
-0.4 (-0.89%)
Day High 
45.135 
Prev. Close
44.87 
1-M High
49.62 
Volume 
1.77M 
Bid
44.5
Ask
44.8
Day Low
44.07 
Open
45.135 
1-M Low
39.85 
Market Cap 
12.24B 
Currency USD 
P/E 20.49 
%Yield -- 
10-SMA 44.72 
20-SMA 43.99 
50-SMA 42.64 
52-W High 49.62 
52-W Low 22.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.19/2.88
Enterprise Value
12.43B
Balance Sheet
Book Value Per Share
7.81
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
10.50M
Operating Revenue Per Share
6.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.05 -1.025 -7.28%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.16 +0.32 +5.48%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.15 +0.23 +3.89%
Quotes are at least 15-min delayed:2025/07/21 07:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.